Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 11 | 2021 | 25 | 2.130 |
Why?
|
| Strongylida Infections | 2 | 2022 | 29 | 0.800 |
Why?
|
| Angiostrongylus cantonensis | 2 | 2022 | 36 | 0.790 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 245 | 0.640 |
Why?
|
| Microcephaly | 2 | 2016 | 21 | 0.610 |
Why?
|
| Bacteremia | 1 | 2019 | 37 | 0.600 |
Why?
|
| Infant | 14 | 2025 | 1175 | 0.550 |
Why?
|
| Osteomyelitis | 2 | 2025 | 20 | 0.540 |
Why?
|
| Doxycycline | 1 | 2017 | 32 | 0.540 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 432 | 0.520 |
Why?
|
| Child, Preschool | 14 | 2025 | 1546 | 0.500 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 163 | 0.480 |
Why?
|
| Bacteria | 1 | 2019 | 293 | 0.480 |
Why?
|
| Child | 17 | 2025 | 3443 | 0.470 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 117 | 0.440 |
Why?
|
| Hawaii | 9 | 2024 | 2011 | 0.330 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 94 | 0.310 |
Why?
|
| Cost of Illness | 1 | 2010 | 98 | 0.300 |
Why?
|
| Echocardiography | 3 | 2019 | 167 | 0.300 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 34 | 0.300 |
Why?
|
| Pneumococcal Infections | 1 | 2009 | 33 | 0.300 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 67 | 0.290 |
Why?
|
| Neoplasms | 1 | 2019 | 1377 | 0.280 |
Why?
|
| Brain | 1 | 2016 | 1472 | 0.270 |
Why?
|
| Humans | 26 | 2025 | 43102 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 306 | 0.260 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 306 | 0.260 |
Why?
|
| Incidence | 6 | 2021 | 1078 | 0.260 |
Why?
|
| Female | 17 | 2025 | 24698 | 0.250 |
Why?
|
| Adolescent | 9 | 2019 | 6081 | 0.250 |
Why?
|
| Male | 17 | 2025 | 23409 | 0.250 |
Why?
|
| Infant, Newborn | 5 | 2022 | 972 | 0.250 |
Why?
|
| Hospitalization | 3 | 2010 | 485 | 0.250 |
Why?
|
| Aspirin | 2 | 2013 | 89 | 0.240 |
Why?
|
| Age Distribution | 4 | 2010 | 249 | 0.230 |
Why?
|
| Discitis | 1 | 2025 | 1 | 0.230 |
Why?
|
| Neisseriaceae Infections | 1 | 2025 | 1 | 0.230 |
Why?
|
| Kingella kingae | 1 | 2025 | 1 | 0.230 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 37 | 0.220 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2544 | 0.210 |
Why?
|
| DNA, Bacterial | 1 | 2025 | 206 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 146 | 0.210 |
Why?
|
| Chickenpox Vaccine | 1 | 2022 | 2 | 0.190 |
Why?
|
| Chickenpox | 1 | 2022 | 6 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 12 | 0.190 |
Why?
|
| Herpes Zoster | 1 | 2022 | 12 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 384 | 0.190 |
Why?
|
| Eosinophilia | 1 | 2022 | 17 | 0.190 |
Why?
|
| Neutralization Tests | 1 | 2021 | 57 | 0.180 |
Why?
|
| Coronary Aneurysm | 2 | 2019 | 3 | 0.180 |
Why?
|
| Coronary Vessels | 2 | 2019 | 92 | 0.170 |
Why?
|
| Cluster Analysis | 1 | 2021 | 207 | 0.170 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2010 | 3 | 0.170 |
Why?
|
| Albendazole | 1 | 2020 | 8 | 0.160 |
Why?
|
| Anthelmintics | 1 | 2020 | 23 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 64 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2013 | 17 | 0.160 |
Why?
|
| Gram-Positive Bacteria | 1 | 2019 | 21 | 0.150 |
Why?
|
| Gram-Negative Bacteria | 1 | 2019 | 29 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2010 | 67 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2020 | 246 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 14 | 0.140 |
Why?
|
| Elastin | 1 | 2017 | 40 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 49 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2010 | 224 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2017 | 317 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2010 | 863 | 0.120 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2016 | 40 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 375 | 0.120 |
Why?
|
| Placenta | 1 | 2016 | 117 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 719 | 0.110 |
Why?
|
| Mothers | 1 | 2016 | 215 | 0.110 |
Why?
|
| Appendicitis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Pregnancy | 2 | 2016 | 1772 | 0.100 |
Why?
|
| Community-Acquired Infections | 2 | 2010 | 22 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2017 | 1600 | 0.100 |
Why?
|
| Wind | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 1759 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 187 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 12 | 0.080 |
Why?
|
| Methicillin Resistance | 1 | 2010 | 12 | 0.080 |
Why?
|
| Probability | 1 | 2010 | 82 | 0.080 |
Why?
|
| Animals | 3 | 2022 | 16992 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 179 | 0.070 |
Why?
|
| Fever | 2 | 2008 | 62 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 259 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 1067 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2025 | 515 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 44 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 113 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2024 | 17 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2024 | 48 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 11 | 0.050 |
Why?
|
| Adult | 3 | 2016 | 13872 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 229 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 611 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 16 | 0.050 |
Why?
|
| Paralysis | 1 | 2022 | 5 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 13 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2002 | 15 | 0.050 |
Why?
|
| Registries | 1 | 2005 | 437 | 0.050 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 25 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2022 | 75 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 95 | 0.050 |
Why?
|
| Torque teno virus | 1 | 2002 | 9 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Ammonium Chloride | 1 | 2021 | 4 | 0.050 |
Why?
|
| Convalescence | 1 | 2021 | 7 | 0.050 |
Why?
|
| Defective Viruses | 1 | 2021 | 10 | 0.050 |
Why?
|
| DNA Virus Infections | 1 | 2002 | 16 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 20 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 27 | 0.050 |
Why?
|
| New Zealand | 1 | 2021 | 32 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 24 | 0.050 |
Why?
|
| Prevalence | 3 | 2016 | 1612 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2022 | 92 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 141 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 64 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 112 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2021 | 148 | 0.040 |
Why?
|
| Virus Integration | 1 | 2002 | 65 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 98 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2021 | 165 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2021 | 186 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 117 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 317 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1604 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 247 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 458 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 355 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2021 | 883 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 167 | 0.040 |
Why?
|
| Acute Disease | 2 | 2013 | 155 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3994 | 0.030 |
Why?
|
| Blood Banks | 1 | 2016 | 10 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 667 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1857 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 86 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1081 | 0.030 |
Why?
|
| HIV-1 | 1 | 2021 | 755 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 6 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 77 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 238 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 139 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 348 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 22 | 0.020 |
Why?
|
| United States | 1 | 2021 | 5205 | 0.020 |
Why?
|
| California | 1 | 2011 | 548 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 30 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 53 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 63 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 115 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 96 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 135 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5080 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 13 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 36 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2002 | 81 | 0.010 |
Why?
|
| HIV | 1 | 2002 | 100 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 245 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 455 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 220 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2002 | 311 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 983 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 318 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1542 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 486 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 2586 | 0.000 |
Why?
|